Thrombocytopenia after Treatment with Danazol
- 28 August 1986
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 315 (9) , 585
- https://doi.org/10.1056/nejm198608283150915
Abstract
To the Editor: Danazol (Danocrine) is a synthetic androgen approved for use in the treatment of fibrocystic breast disorder, endometriosis, and hereditary angioedema. It has also been used in the treatment of chronic immune thrombocytopenic purpura (ITP).1 , 2 The mechanism of its action in ITP is unknown; presumably, it acts as an immune modulator. From 1979 through 1985, the Food and Drug Administration received four reports of thrombocytopenia after treatment with danazol. This letter summarizes those reports.The reports were received through the system for reporting adverse drug reactions. Four women (22 to 49 years of age; mean age, 36) were . . .Keywords
This publication has 2 references indexed in Scilit:
- The use of danazol in the management of chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 1985
- Danazol for the Treatment of Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 1983